Personalized therapy for breast cancer: a dream or a reality?

Breast cancer oncology represents one of the disciplines where personalized cancer medicine has been most actively pursued. The class-discovery studies conceptually advanced the field, underlining the molecular heterogeneity governing this common disease. The advent of high-throughput molecular profiling technologies holds great promise for the advance of all aspects of personalized cancer medicine, namely accurate prognostication, prediction of response to common systemic therapies and individualized monitoring of the disease. Moreover, an ever-expanding arsenal of targeted therapeutic compounds under clinical development, coupled with emerging powerful tools for comprehensive molecular and functional characterization, pose significant promise for improved clinical outcomes for breast cancer patients. Interrogation of the germline genetic variation offers further promise towards tailoring of breast cancer management. Well-conducted prospective validation studies are needed if breast cancer personalized therapy is to transform from a dream into a reality.

[1]  Sung-Bae Kim,et al.  Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. , 2012, The New England journal of medicine.

[2]  R. Tibshirani,et al.  Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[3]  L. Esserman,et al.  A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. , 2011, JAMA.

[4]  J. Bergh,et al.  Strong Time Dependence of the 76-Gene Prognostic Signature for Node-Negative Breast Cancer Patients in the TRANSBIG Multicenter Independent Validation Series , 2007, Clinical Cancer Research.

[5]  C. Sotiriou,et al.  Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures , 2007, Breast Cancer Research.

[6]  M. Cronin,et al.  Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  G. Hortobagyi,et al.  18F-FDG PET/CT Findings and Circulating Tumor Cell Counts in the Monitoring of Systemic Therapies for Bone Metastases from Breast Cancer , 2010, The Journal of Nuclear Medicine.

[8]  G. Hortobagyi,et al.  Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[10]  N. Cohen,et al.  Open innovation networks between academia and industry: an imperative for breakthrough therapies , 2009, Nature Medicine.

[11]  A. Sivachenko,et al.  Sequence analysis of mutations and translocations across breast cancer subtypes , 2012, Nature.

[12]  Joseph P. Costantino,et al.  Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20 , 2011, Breast Cancer Research and Treatment.

[13]  Adam A. Margolin,et al.  The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.

[14]  Giulia Bianchi,et al.  Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. , 2012, The Lancet. Oncology.

[15]  Gary H Lyman,et al.  Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer. , 2005, The American journal of managed care.

[16]  Yusuke Nakamura,et al.  Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Joseph A DiMasi,et al.  Economics of new oncology drug development. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Carlo C. Maley,et al.  Clonal evolution in cancer , 2012, Nature.

[19]  S. Ramaswamy,et al.  Systematic identification of genomic markers of drug sensitivity in cancer cells , 2012, Nature.

[20]  S. Loi,et al.  Phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway inhibition: a breakthrough in the management of luminal (ER+/HER2−) breast cancers? , 2012, Current opinion in oncology.

[21]  G. Giaccone,et al.  Drug Development: Portals of Discovery , 2012, Clinical Cancer Research.

[22]  K. Wade,et al.  Practice-Based Research , 2007, Social work in health care.

[23]  G. Verdine,et al.  The Challenge of Drugging Undruggable Targets in Cancer: Lessons Learned from Targeting BCL-2 Family Members , 2007, Clinical Cancer Research.

[24]  A. Børresen-Dale,et al.  The Life History of 21 Breast Cancers , 2012, Cell.

[25]  H. Linden,et al.  Gene expression profiling and breast cancer care: What are the potential benefits and policy implications? , 2005, Genetics in Medicine.

[26]  Philip M. Long,et al.  Breast cancer classification and prognosis based on gene expression profiles from a population-based study , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[27]  Lajos Pusztai,et al.  Gene-expression signatures in breast cancer. , 2009, The New England journal of medicine.

[28]  H. McLeod,et al.  Tamoxifen and CYP2D6: a contradiction of data. , 2012, The oncologist.

[29]  M. Ringnér,et al.  Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity , 2007, Proceedings of the National Academy of Sciences.

[30]  E. Lianidou,et al.  Molecular characterization of circulating tumor cells in breast cancer: challenges and promises for individualized cancer treatment , 2012, Cancer and Metastasis Reviews.

[31]  Michele De Palma,et al.  The biology of personalized cancer medicine: Facing individual complexities underlying hallmark capabilities , 2012, Molecular oncology.

[32]  I. Ellis,et al.  An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer , 2007, Genome Biology.

[33]  M. Ratain,et al.  Germline pharmacogenomics in oncology: Decoding the patient for targeting therapy , 2012, Molecular oncology.

[34]  M. Stratton,et al.  Use of cancer‐specific genomic rearrangements to quantify disease burden in plasma from patients with solid tumors , 2010, Genes, chromosomes & cancer.

[35]  A. Musolino,et al.  Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  R. Bernards.  It's Diagnostics, Stupid , 2010, Cell.

[37]  Tanja Fehm,et al.  Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients , 2009, Breast Cancer Research.

[38]  Peter Regitnig,et al.  Genomic index of sensitivity to endocrine therapy for breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[40]  Gordon B Mills,et al.  mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. , 2006, Cancer research.

[41]  A. Ashworth,et al.  Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer. , 2008, Cancer cell.

[42]  Alan Ashworth,et al.  Translating cancer research into targeted therapeutics , 2010, Nature.

[43]  Irmtraud M. Meyer,et al.  The clonal and mutational evolution spectrum of primary triple-negative breast cancers , 2012, Nature.

[44]  Joe W. Gray,et al.  What are we learning from the cancer genome? , 2012, Nature Reviews Clinical Oncology.

[45]  L. Esserman,et al.  A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer , 2010, Breast Cancer Research.

[46]  F. Pépin,et al.  Stromal gene expression predicts clinical outcome in breast cancer , 2008, Nature Medicine.

[47]  I. Weinstein.  Addiction to Oncogenes--the Achilles Heal of Cancer , 2002, Science.

[48]  Gianluca Bontempi,et al.  Biological Processes Associated with Breast Cancer Clinical Outcome Depend on the Molecular Subtypes , 2008, Clinical Cancer Research.

[49]  M. Gerlinger,et al.  How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine , 2010, British Journal of Cancer.

[50]  Joshua F. McMichael,et al.  Whole Genome Analysis Informs Breast Cancer Response to Aromatase Inhibition , 2012, Nature.

[51]  Jorge S. Reis-Filho,et al.  Molecular Profiling: Moving Away from Tumor Philately , 2010, Science Translational Medicine.

[52]  Yuan Qi,et al.  Multifactorial approach to predicting resistance to anthracyclines. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  Zoltan Szallasi,et al.  Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer , 2010, Nature Medicine.

[54]  Adrian V. Lee,et al.  Insulin-like growth factor-I activates gene transcription programs strongly associated with poor breast cancer prognosis. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  L. V. van't Veer,et al.  Clinical application of the 70-gene profile: the MINDACT trial. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  G. Hortobagyi,et al.  Circulating tumor cells and bone metastases as detected by FDG-PET/CT in patients with metastatic breast cancer. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[57]  D. Sargent,et al.  Biomarkers and surrogate end points—the challenge of statistical validation , 2010, Nature Reviews Clinical Oncology.

[58]  D. Christiani,et al.  Germline genetic variation, cancer outcome, and pharmacogenetics. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  Alison Stopeck,et al.  Circulating tumor cells, disease progression, and survival in metastatic breast cancer. , 2004, The New England journal of medicine.

[60]  Jian Jin,et al.  Dynamic Reprogramming of the Kinome in Response to Targeted MEK Inhibition in Triple-Negative Breast Cancer , 2012, Cell.

[61]  Paul Ellis,et al.  PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor–positive breast cancer , 2010, Proceedings of the National Academy of Sciences.

[62]  Robert B Livingston,et al.  Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. , 2010, The Lancet. Oncology.

[63]  S. Hanash,et al.  Emerging molecular biomarkers—blood-based strategies to detect and monitor cancer , 2011, Nature Reviews Clinical Oncology.

[64]  D. Hayes,et al.  Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[65]  Annuska M. Glas,et al.  The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer , 2010, Breast Cancer Research and Treatment.

[66]  P. Goodwin,et al.  Prognosis of BRCA-associated breast cancer: a summary of evidence , 2009, Breast Cancer Research and Treatment.

[67]  Tanja Fehm,et al.  Expression of stem cell and epithelial-mesenchymal transition markers in primary breast cancer patients with circulating tumor cells , 2012, Breast Cancer Research.

[68]  John Quackenbush,et al.  Characterization and Clinical Evaluation of CD10+ Stroma Cells in the Breast Cancer Microenvironment , 2012, Clinical Cancer Research.

[69]  S. Paik,et al.  Development of the 21-gene assay and its application in clinical practice and clinical trials. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[70]  A. Børresen-Dale,et al.  The landscape of cancer genes and mutational processes in breast cancer , 2012, Nature.

[71]  René Bernards,et al.  A Missing Link in Genotype-Directed Cancer Therapy , 2012, Cell.

[72]  Sean C. Bendall,et al.  From single cells to deep phenotypes in cancer , 2012, Nature Biotechnology.

[73]  J. Westfall,et al.  Practice-based research--"Blue Highways" on the NIH roadmap. , 2007, JAMA.

[74]  Francisco M. De La Vega,et al.  Development of Personalized Tumor Biomarkers Using Massively Parallel Sequencing , 2010, Science Translational Medicine.